KBC Group’s Rapport Therapeutics RAPP Stock Holding History

KBC Group’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40K	Hold	962	–	–	﹤0.01%	1775
2026 Q1	$30K	Buy	+962	New	+$27.1K	﹤0.01%	1799

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

KBC Group's RAPP Position: Q2 2026 in Review

KBC Group held its Rapport Therapeutics (RAPP) position steady in Q2 2026 at 962 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #1775.

KBC Group first reported a position in RAPP in Q1 2026 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

KBC Group held 962 shares of Rapport Therapeutics worth $40K as of Q2 2026.
KBC Group left its Rapport Therapeutics share count unchanged in Q2 2026.
Rapport Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1775 holding.
KBC Group first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 2 quarters since.
161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.